Tuberculosis Treatment with Levofloxacin and Ethambutol

Indications and Regimens

The World Health Organization recommends a shorter all-oral regimen with a 5-month continuation phase that includes levofloxacin, clofazimine, pyrazinamide, and ethambutol for MDR/RR-TB patients 1
This combination is specifically indicated following a 4-6 month intensive phase of treatment with bedaquiline, fluoroquinolone, clofazimine, pyrazinamide, ethambutol, high-dose isoniazid, and ethionamide 1
Levofloxacin is generally preferred over moxifloxacin due to fewer adverse events and less QTc prolongation when used in combination regimens 1

In the WHO classification system for MDR-TB drugs, levofloxacin is a Group A drug while ethambutol is a Group C drug 1, 2
Ethambutol dosing should be weight-based, typically 15-20 mg/kg daily in the continuation phase 3

For the shorter MDR/RR-TB regimen, the continuation phase with levofloxacin and ethambutol has a fixed duration of 5 months 1, 2
Regular monitoring is essential when using this combination, including monitoring for optic neuritis with ethambutol and tendinopathy, peripheral neuropathy, and QTc prolongation with levofloxacin 1, 3

Drug susceptibility testing should be performed, particularly for fluoroquinolones, before initiating this combination 4
In patients with renal impairment, dose adjustments may be necessary for both drugs 3

For drug-susceptible TB, the standard continuation phase remains isoniazid and rifampicin for 4 months 5, 6
The levofloxacin-ethambutol combination is primarily indicated for drug-resistant TB scenarios 1